The work described above identified potential biomarkers that may be of use in predicting outcomes depending on therapy (surgery, PET, adjuvant endocrine therapy) and survival in older women with primary breast cancer, including novel markers not currently used in clinical practice such as cytoplastic cyclin-E [17] and liver kinase-B1 [18]. This evidence concerns the gene STK11 and breast carcinoma.